CA3002884A1 - Protein kinase inhibitors, preparation method and medical use thereof - Google Patents

Protein kinase inhibitors, preparation method and medical use thereof Download PDF

Info

Publication number
CA3002884A1
CA3002884A1 CA3002884A CA3002884A CA3002884A1 CA 3002884 A1 CA3002884 A1 CA 3002884A1 CA 3002884 A CA3002884 A CA 3002884A CA 3002884 A CA3002884 A CA 3002884A CA 3002884 A1 CA3002884 A1 CA 3002884A1
Authority
CA
Canada
Prior art keywords
compound
mixture
racemate
diastereomer
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3002884A
Other languages
English (en)
French (fr)
Inventor
Lei YIN
Wenjian LIU
Heng Li
Dianxi ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3002884(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of CA3002884A1 publication Critical patent/CA3002884A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3002884A 2015-11-30 2016-11-28 Protein kinase inhibitors, preparation method and medical use thereof Pending CA3002884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510856641.1 2015-11-30
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (zh) 2015-11-30 2016-11-28 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CA3002884A1 true CA3002884A1 (en) 2017-06-08

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002884A Pending CA3002884A1 (en) 2015-11-30 2016-11-28 Protein kinase inhibitors, preparation method and medical use thereof

Country Status (21)

Country Link
US (2) US11091476B2 (enExample)
EP (1) EP3385262B1 (enExample)
JP (2) JP6921101B2 (enExample)
KR (1) KR20180083421A (enExample)
CN (3) CN106810536A (enExample)
AU (1) AU2016365366B2 (enExample)
BR (1) BR112018010879A2 (enExample)
CA (1) CA3002884A1 (enExample)
CO (1) CO2018005854A2 (enExample)
DK (1) DK3385262T3 (enExample)
ES (1) ES2928169T3 (enExample)
HU (1) HUE060152T2 (enExample)
IL (1) IL259711B (enExample)
MA (1) MA42341B2 (enExample)
MX (1) MX387207B (enExample)
PH (1) PH12018550049A1 (enExample)
PT (1) PT3385262T (enExample)
RU (1) RU2749437C2 (enExample)
UA (1) UA124001C2 (enExample)
WO (1) WO2017092635A1 (enExample)
ZA (1) ZA201803531B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2020253865A1 (zh) 2019-06-21 2020-12-24 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
EP4214213A1 (en) * 2020-09-21 2023-07-26 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
IL316942A (en) * 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
CN117222636B (zh) * 2021-04-12 2026-06-23 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
CN121270553B (zh) * 2025-10-31 2026-05-15 广西医科大学第二附属医院(广西医科大学第二临床医学院) 一种抗肿瘤化合物、抗肿瘤制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) * 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
SG11202001498QA (en) 2017-09-05 2020-03-30 Blackthorn Therapeutics Inc Vasopressin receptor antagonists and products and methods related thereto
CN117222636B (zh) 2021-04-12 2026-06-23 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
EP3385262A4 (en) 2019-06-19
MX2018006370A (es) 2018-09-24
RU2018122864A3 (enExample) 2020-03-17
US11787801B2 (en) 2023-10-17
RU2749437C2 (ru) 2021-06-10
CN108290864A (zh) 2018-07-17
BR112018010879A2 (pt) 2018-11-21
JP2021138737A (ja) 2021-09-16
DK3385262T3 (da) 2022-10-10
AU2016365366A1 (en) 2018-05-17
PH12018550049A1 (en) 2018-10-29
US20210371418A1 (en) 2021-12-02
JP2019500413A (ja) 2019-01-10
US11091476B2 (en) 2021-08-17
MA42341B2 (fr) 2021-05-31
CN108290864B (zh) 2022-05-10
PT3385262T (pt) 2022-10-18
JP6921101B2 (ja) 2021-08-18
IL259711A (en) 2018-07-31
IL259711B (en) 2022-08-01
HUE060152T2 (hu) 2023-02-28
MA42341A1 (fr) 2018-06-29
UA124001C2 (uk) 2021-07-07
ES2928169T3 (es) 2022-11-15
RU2018122864A (ru) 2020-01-13
US20200165239A1 (en) 2020-05-28
CN113956238A (zh) 2022-01-21
WO2017092635A1 (zh) 2017-06-08
EP3385262A1 (en) 2018-10-10
KR20180083421A (ko) 2018-07-20
CN106810536A (zh) 2017-06-09
AU2016365366B2 (en) 2021-03-04
MX387207B (es) 2025-03-18
CN113956238B (zh) 2023-07-14
EP3385262B1 (en) 2022-07-13
CO2018005854A2 (es) 2018-06-20
ZA201803531B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US11787801B2 (en) Protein kinase inhibitors, preparation method and medical use thereof
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP2019500413A5 (enExample)
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
AU2017389818B2 (en) Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
WO2021043208A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
JP6785876B2 (ja) ピリド［３，４−ｄ］ピリミジン誘導体及びその薬学的に許容される塩
JP2020504139A (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
JP2018135268A (ja) 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
CA3024831A1 (en) Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative
CN115724844B (zh) 一种具有抗肿瘤活性的杂环化合物及其用途
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
KR20240128040A (ko) 2 고리성 골격을 갖는 1h-피라졸-3-아민 유도체
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
HK1260629A1 (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
HK1260629B (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
WO2025007026A1 (en) Heterobifunctional compounds and methods of use thereof
CN117677614A (zh) 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
EA049737B1 (ru) Производное 1h-пиразол-3-амина, имеющее бициклическую основную цепь
WO2021143821A1 (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211110

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260227